700 Stock Overview Provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Certara, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Certara Historical stock prices Current Share Price US$9.62 52 Week High US$10.68 52 Week Low US$9.62 Beta 1.53 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change -56.27% 5 Year Change n/a Change since IPO -57.81%
Recent News & Updates
Third quarter 2024 earnings released: US$0.009 loss per share (vs US$0.31 loss in 3Q 2023) Nov 07
Certara, Inc. Updates Earnings Guidance for the Year 2024 Nov 07
Certara, Inc. Appoints John Reynders as Independent Board Member Oct 17
Certara, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 10
Certara, Inc. (NasdaqGS:CERT) completed the acquisition of ChemAxon Kft. Oct 04
Certara, Inc. Launches Phoenix™ Version 8.5 Drug Development Software Aug 16 See more updates
Third quarter 2024 earnings released: US$0.009 loss per share (vs US$0.31 loss in 3Q 2023) Nov 07
Certara, Inc. Updates Earnings Guidance for the Year 2024 Nov 07
Certara, Inc. Appoints John Reynders as Independent Board Member Oct 17
Certara, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 10
Certara, Inc. (NasdaqGS:CERT) completed the acquisition of ChemAxon Kft. Oct 04
Certara, Inc. Launches Phoenix™ Version 8.5 Drug Development Software Aug 16
Certara, Inc. Reiterates Earnings Guidance for the Year 2024 Aug 07
Certara, Inc. (NasdaqGS:CERT)signed a definitive agreement to acquire ChemAxon Kft. Jul 10
Certara, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 04
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software Jun 18
Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel May 22
Certara, Inc. Reiterates Earnings Guidance for the Year 2024 May 09
Certara, Inc. Launches Cloud Platform to Further Unify Its End-To-End Scientific Software Platform Apr 16
Certara, Inc., Annual General Meeting, May 21, 2024 Apr 11
Certara, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 10
Certara, Inc. Provides Earnings Guidance for the Year 2024 Mar 01
Certara, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 02
Certara, Inc. (NasdaqGS : CERT) acquired Applied BioMath, LLC. Dec 14
Certara, Inc. Announces the Introduction of Simcyp Biopharmaceutics Software Nov 22
Certara, Inc. Provides Revenue Guidance for the Year 2023 Nov 10
Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.025 profit in 3Q 2022) Nov 10
Certara, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 12
Certara, Inc. Updates Earnings Guidance for the Year 2023 Aug 10
Second quarter 2023 earnings released: EPS: US$0.03 (vs US$0.004 loss in 2Q 2022) Aug 10
New major risk - Share price stability Aug 05
Certara, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 14
First quarter 2023 earnings released: EPS: US$0.009 (vs US$0.014 in 1Q 2022) May 09
Certara, Inc. Provides Revenue Guidance for the Year 2023 May 09
Full year 2022 earnings released: EPS: US$0.094 (vs US$0.089 loss in FY 2021) Mar 03
Certara, Inc. to Report Q4, 2022 Results on Mar 01, 2023 Feb 02
Certara, Inc. (NasdaqGS:CERT) acquired VYASA Analytics LLC. Jan 05
Forecast breakeven date pushed back to 2023 Dec 31
Certara, Inc. Announces the Resignation of Mason Slaine as Director of the Company Dec 26 Arsenal Capital Partners completed the acquisition of an additional 18.8% stake in Certara, Inc. (NasdaqGS:CERT) from EQT Avatar Parent L.P.
Certara, Inc. Appoints David Spaight to the Board of Directors Dec 09
Now 21% undervalued after recent price drop Nov 24
Independent Director recently sold €172k worth of stock Nov 16
Third quarter 2022 earnings released: EPS: US$0.025 (vs US$0.012 loss in 3Q 2021) Nov 09 Certara, Inc. Reaffirms Earnings Guidance for the Full Year 2022
Japan's Pharmaceuticals and Medical Devices Agency Renews Licenses of Certara's Software for Evaluating Regulatory Submissions Oct 20
Certara, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 14
Insider recently sold €3.1m worth of stock Aug 18
Now 21% undervalued Aug 13
Certara, Inc. Announces Resignation of Justin Edge as President of Regulatory and Access, Effective September 1, 2022 Aug 13
Second quarter 2022 earnings released: US$0.004 loss per share (vs US$0.019 loss in 2Q 2021) Aug 10
Certara, Inc. Revises Its Full Year Earnings Guidance of 2022 Aug 10
Certara, Inc. Introduces Update of Pinnacle 21(Tm) Enterprise and New Pinnacle 21(Tm) Data Exchange Module Aug 06
Certara, Inc. Appoints Rosemary A. Crane, as a Class III Director, Effective July 21, 2022 Jul 26
Certara, Inc. Appoints Eran Broshy as New Independent Board Member, Effective July 11, 2022 Jul 14
Certara, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 13
Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development Jun 29
Certara, Inc. Announces New Versions of Biosimulation Software for Development of Novel Biologics Jun 22
Insider recently sold €4.6m worth of stock Jun 04
First quarter 2022 earnings released: EPS: US$0.014 (vs US$0.007 in 1Q 2021) May 06
Certara, Inc. Reiterates Earnings Guidance for the Year 2022 May 06
Certara, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 21
Certara, Inc. Announces Committee Changes Apr 14 Certara, Inc. Announces Resignation of Dr. Carol Gallagher, Member of the Board of Directors, Chair of the Compensation Committee, and Member of the Nominating and Corporate Governance Committee
Insider recently sold €4.5m worth of stock Mar 21
Certara, Inc. Revises Earnings Guidance for the Year 2022 Mar 03
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 03
U.S. Food and Drug Administration Licenses Certara, Inc.’s Immunogenicity Simulator Feb 24
Certara, Inc. Receives 90% of New Drug Approvals by the U.S. Food and Drug Administration’s Center for Drug Evaluation and Review Feb 16
Certara, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 09
Certara, Inc. Announces Release of Pinnacle 21 Enterprise Software Dec 14
Certara, Inc. Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances Dec 03
Independent Chairman of the Board Sherilyn S. McCoy has left the company Dec 03
Certara, Inc. Announces Update of D360 Scientific Informatics Software Nov 30
Insider recently sold €9.9m worth of stock Nov 25
Third quarter 2021 earnings released: US$0.012 loss per share (vs US$0.009 profit in 3Q 2020) Nov 10
Forecast to breakeven in 2022 Sep 23
Certara Receives FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation Sep 21
Certara, Inc. has completed a Follow-on Equity Offering in the amount of $620 million. Sep 10
Forecast breakeven pushed back to 2022 Aug 12 Certara, Inc. Revises Earnings Guidance for the Full Year 2021
Forecast breakeven moved forward to 2021 Jul 23
Certara, Inc. (NasdaqGS:CERT) acquired Insight Medical Writing Limited. Jun 12
Certara, Inc. Releases New Versions of Its Preeminent Quantitative Systems Pharmacology Simulators for Expediting Development of Biologics and Immuno-Oncology Therapies May 14
First quarter 2021 earnings released: EPS US$0.007 (vs US$0.045 loss in 1Q 2020) May 07
Certara, Inc. Revised Financial Guidance for the Full Year of 2021 May 07
Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier May 05
Full year 2020 earnings released: US$0.37 loss per share (vs US$0.067 loss in FY 2019) Mar 17
Neonmind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity Mar 12 Shareholder Returns 700 DE Healthcare Services DE Market 7D 0% -0.02% 0.3% 1Y n/a -17.8% 8.4%
See full shareholder returns
Return vs Market: Insufficient data to determine how 700 performed against the German Market .
Price Volatility Is 700's price volatile compared to industry and market? 700 volatility 700 Average Weekly Movement n/a Healthcare Services Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 700's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 700's volatility change over the past year.
About the Company Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions.
Show more Certara, Inc. Fundamentals Summary How do Certara's earnings and revenue compare to its market cap? 700 fundamental statistics Market cap €1.66b Earnings (TTM ) -€30.11m Revenue (TTM ) €361.13m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 700 income statement (TTM ) Revenue US$372.80m Cost of Revenue US$150.32m Gross Profit US$222.48m Other Expenses US$253.56m Earnings -US$31.08m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.19 Gross Margin 59.68% Net Profit Margin -8.34% Debt/Equity Ratio 28.1%
How did 700 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 19:41 End of Day Share Price 2024/11/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Certara, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joseph Vruwink Baird Luke Sergott Barclays Andrew Moss BofA Global Research
Show 14 more analysts 